nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—PTGS2—esophageal cancer	0.438	1	CbGaD
Etoricoxib—PTGS2—Cisplatin—esophageal cancer	0.0791	0.496	CbGbCtD
Etoricoxib—CYP2C9—Capecitabine—esophageal cancer	0.0534	0.335	CbGbCtD
Etoricoxib—CYP2C9—Cisplatin—esophageal cancer	0.0269	0.169	CbGbCtD
Etoricoxib—Celecoxib—CA2—esophageal cancer	0.00363	0.648	CrCbGaD
Etoricoxib—MAPK14—neck—esophageal cancer	0.00232	0.151	CbGeAlD
Etoricoxib—MAPK14—epithelium—esophageal cancer	0.00158	0.103	CbGeAlD
Etoricoxib—MAPK14—bronchus—esophageal cancer	0.00156	0.101	CbGeAlD
Etoricoxib—MAPK14—smooth muscle tissue—esophageal cancer	0.00152	0.0988	CbGeAlD
Etoricoxib—MAPK14—digestive system—esophageal cancer	0.0012	0.078	CbGeAlD
Etoricoxib—Celecoxib—PTGS2—esophageal cancer	0.00114	0.203	CrCbGaD
Etoricoxib—MAPK14—lung—esophageal cancer	0.00101	0.0652	CbGeAlD
Etoricoxib—Vismodegib—ABCB1—esophageal cancer	0.00083	0.148	CrCbGaD
Etoricoxib—MAPK14—lymph node—esophageal cancer	0.000687	0.0446	CbGeAlD
Etoricoxib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000657	0.00396	CcSEcCtD
Etoricoxib—Proteinuria—Methotrexate—esophageal cancer	0.000627	0.00378	CcSEcCtD
Etoricoxib—Protein urine present—Methotrexate—esophageal cancer	0.000619	0.00373	CcSEcCtD
Etoricoxib—Diabetes mellitus—Capecitabine—esophageal cancer	0.000618	0.00372	CcSEcCtD
Etoricoxib—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000618	0.00372	CcSEcCtD
Etoricoxib—Pancreatitis—Cisplatin—esophageal cancer	0.000618	0.00372	CcSEcCtD
Etoricoxib—Gastroenteritis—Capecitabine—esophageal cancer	0.000606	0.00365	CcSEcCtD
Etoricoxib—Abdominal discomfort—Cisplatin—esophageal cancer	0.000604	0.00364	CcSEcCtD
Etoricoxib—Herpes simplex—Methotrexate—esophageal cancer	0.000598	0.0036	CcSEcCtD
Etoricoxib—Hepatic failure—Capecitabine—esophageal cancer	0.000598	0.0036	CcSEcCtD
Etoricoxib—Atrial fibrillation—Capecitabine—esophageal cancer	0.000567	0.00342	CcSEcCtD
Etoricoxib—Renal impairment—Capecitabine—esophageal cancer	0.000565	0.0034	CcSEcCtD
Etoricoxib—Thirst—Capecitabine—esophageal cancer	0.000565	0.0034	CcSEcCtD
Etoricoxib—Blood uric acid increased—Methotrexate—esophageal cancer	0.000561	0.00338	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000554	0.00334	CcSEcCtD
Etoricoxib—Renal failure—Cisplatin—esophageal cancer	0.000552	0.00333	CcSEcCtD
Etoricoxib—Myocardial infarction—Cisplatin—esophageal cancer	0.000551	0.00332	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000551	0.00332	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000549	0.0033	CcSEcCtD
Etoricoxib—Stomatitis—Cisplatin—esophageal cancer	0.000548	0.0033	CcSEcCtD
Etoricoxib—Conjunctivitis—Cisplatin—esophageal cancer	0.000546	0.00329	CcSEcCtD
Etoricoxib—Melaena—Methotrexate—esophageal cancer	0.000538	0.00324	CcSEcCtD
Etoricoxib—Cystitis noninfective—Methotrexate—esophageal cancer	0.000538	0.00324	CcSEcCtD
Etoricoxib—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000538	0.00324	CcSEcCtD
Etoricoxib—Pain in extremity—Capecitabine—esophageal cancer	0.000538	0.00324	CcSEcCtD
Etoricoxib—Cystitis—Methotrexate—esophageal cancer	0.000532	0.00321	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000531	0.0032	CcSEcCtD
Etoricoxib—Vaginal infection—Methotrexate—esophageal cancer	0.00052	0.00314	CcSEcCtD
Etoricoxib—CYP2C19—digestive system—esophageal cancer	0.000512	0.0332	CbGeAlD
Etoricoxib—Cardiac arrest—Capecitabine—esophageal cancer	0.000511	0.00308	CcSEcCtD
Etoricoxib—Blood creatinine increased—Capecitabine—esophageal cancer	0.000504	0.00303	CcSEcCtD
Etoricoxib—Bladder pain—Methotrexate—esophageal cancer	0.000498	0.003	CcSEcCtD
Etoricoxib—Neoplasm—Methotrexate—esophageal cancer	0.000498	0.003	CcSEcCtD
Etoricoxib—Ecchymosis—Methotrexate—esophageal cancer	0.000498	0.003	CcSEcCtD
Etoricoxib—Mouth ulceration—Methotrexate—esophageal cancer	0.000498	0.003	CcSEcCtD
Etoricoxib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000498	0.003	CcSEcCtD
Etoricoxib—Connective tissue disorder—Cisplatin—esophageal cancer	0.000496	0.00299	CcSEcCtD
Etoricoxib—Urethral disorder—Cisplatin—esophageal cancer	0.000494	0.00298	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000491	0.00296	CcSEcCtD
Etoricoxib—Visual impairment—Cisplatin—esophageal cancer	0.000486	0.00293	CcSEcCtD
Etoricoxib—Breast disorder—Capecitabine—esophageal cancer	0.000486	0.00293	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000484	0.00292	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000484	0.00292	CcSEcCtD
Etoricoxib—Gastritis—Capecitabine—esophageal cancer	0.000476	0.00287	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000474	0.00286	CcSEcCtD
Etoricoxib—Muscular weakness—Capecitabine—esophageal cancer	0.000474	0.00286	CcSEcCtD
Etoricoxib—Eye disorder—Cisplatin—esophageal cancer	0.000471	0.00284	CcSEcCtD
Etoricoxib—Tinnitus—Cisplatin—esophageal cancer	0.00047	0.00283	CcSEcCtD
Etoricoxib—Cardiac disorder—Cisplatin—esophageal cancer	0.000468	0.00282	CcSEcCtD
Etoricoxib—Flushing—Cisplatin—esophageal cancer	0.000468	0.00282	CcSEcCtD
Etoricoxib—Abdominal distension—Capecitabine—esophageal cancer	0.000468	0.00282	CcSEcCtD
Etoricoxib—Diabetes mellitus—Methotrexate—esophageal cancer	0.00046	0.00277	CcSEcCtD
Etoricoxib—Bronchospasm—Capecitabine—esophageal cancer	0.000457	0.00275	CcSEcCtD
Etoricoxib—Immune system disorder—Cisplatin—esophageal cancer	0.000456	0.00275	CcSEcCtD
Etoricoxib—PTGS2—epithelium—esophageal cancer	0.000455	0.0295	CbGeAlD
Etoricoxib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000455	0.00274	CcSEcCtD
Etoricoxib—Angina pectoris—Capecitabine—esophageal cancer	0.000453	0.00273	CcSEcCtD
Etoricoxib—Arrhythmia—Cisplatin—esophageal cancer	0.000451	0.00272	CcSEcCtD
Etoricoxib—PTGS2—bronchus—esophageal cancer	0.000448	0.029	CbGeAlD
Etoricoxib—Bronchitis—Capecitabine—esophageal cancer	0.000447	0.00269	CcSEcCtD
Etoricoxib—Alopecia—Cisplatin—esophageal cancer	0.000446	0.00269	CcSEcCtD
Etoricoxib—Abdominal discomfort—Capecitabine—esophageal cancer	0.000445	0.00268	CcSEcCtD
Etoricoxib—Hepatic failure—Methotrexate—esophageal cancer	0.000445	0.00268	CcSEcCtD
Etoricoxib—Malnutrition—Cisplatin—esophageal cancer	0.000439	0.00265	CcSEcCtD
Etoricoxib—Erythema—Cisplatin—esophageal cancer	0.000439	0.00265	CcSEcCtD
Etoricoxib—PTGS2—smooth muscle tissue—esophageal cancer	0.000438	0.0284	CbGeAlD
Etoricoxib—Flatulence—Cisplatin—esophageal cancer	0.000433	0.00261	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000432	0.0026	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000424	0.00256	CcSEcCtD
Etoricoxib—Weight increased—Capecitabine—esophageal cancer	0.000423	0.00255	CcSEcCtD
Etoricoxib—Visual disturbance—Methotrexate—esophageal cancer	0.000422	0.00254	CcSEcCtD
Etoricoxib—Muscle spasms—Cisplatin—esophageal cancer	0.000422	0.00254	CcSEcCtD
Etoricoxib—Hyperglycaemia—Capecitabine—esophageal cancer	0.000419	0.00253	CcSEcCtD
Etoricoxib—CYP1A2—digestive system—esophageal cancer	0.000418	0.0271	CbGeAlD
Etoricoxib—Pneumonia—Capecitabine—esophageal cancer	0.000417	0.00251	CcSEcCtD
Etoricoxib—Infestation NOS—Capecitabine—esophageal cancer	0.000414	0.0025	CcSEcCtD
Etoricoxib—Infestation—Capecitabine—esophageal cancer	0.000414	0.0025	CcSEcCtD
Etoricoxib—Vision blurred—Cisplatin—esophageal cancer	0.000414	0.00249	CcSEcCtD
Etoricoxib—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000413	0.00249	CcSEcCtD
Etoricoxib—Tremor—Cisplatin—esophageal cancer	0.000411	0.00248	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000411	0.00247	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000408	0.00246	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000408	0.00246	CcSEcCtD
Etoricoxib—Renal failure—Capecitabine—esophageal cancer	0.000407	0.00245	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000406	0.00245	CcSEcCtD
Etoricoxib—Myocardial infarction—Capecitabine—esophageal cancer	0.000406	0.00245	CcSEcCtD
Etoricoxib—Anaemia—Cisplatin—esophageal cancer	0.000406	0.00245	CcSEcCtD
Etoricoxib—Stomatitis—Capecitabine—esophageal cancer	0.000404	0.00243	CcSEcCtD
Etoricoxib—Jaundice—Capecitabine—esophageal cancer	0.000404	0.00243	CcSEcCtD
Etoricoxib—Conjunctivitis—Capecitabine—esophageal cancer	0.000403	0.00243	CcSEcCtD
Etoricoxib—Urinary tract infection—Capecitabine—esophageal cancer	0.000403	0.00243	CcSEcCtD
Etoricoxib—PTGS2—trachea—esophageal cancer	0.000402	0.0261	CbGeAlD
Etoricoxib—CYP2C9—digestive system—esophageal cancer	0.000397	0.0257	CbGeAlD
Etoricoxib—Haematuria—Capecitabine—esophageal cancer	0.000395	0.00238	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000392	0.00236	CcSEcCtD
Etoricoxib—Epistaxis—Capecitabine—esophageal cancer	0.000391	0.00235	CcSEcCtD
Etoricoxib—CYP2E1—digestive system—esophageal cancer	0.000376	0.0244	CbGeAlD
Etoricoxib—Haemoglobin—Capecitabine—esophageal cancer	0.000374	0.00225	CcSEcCtD
Etoricoxib—Anxiety—Cisplatin—esophageal cancer	0.000373	0.00224	CcSEcCtD
Etoricoxib—Hepatitis—Capecitabine—esophageal cancer	0.000372	0.00224	CcSEcCtD
Etoricoxib—Haemorrhage—Capecitabine—esophageal cancer	0.000372	0.00224	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000371	0.00224	CcSEcCtD
Etoricoxib—Hypoaesthesia—Capecitabine—esophageal cancer	0.00037	0.00223	CcSEcCtD
Etoricoxib—Pharyngitis—Capecitabine—esophageal cancer	0.000369	0.00222	CcSEcCtD
Etoricoxib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000367	0.00221	CcSEcCtD
Etoricoxib—Oedema peripheral—Capecitabine—esophageal cancer	0.000366	0.00221	CcSEcCtD
Etoricoxib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000365	0.0022	CcSEcCtD
Etoricoxib—Urethral disorder—Capecitabine—esophageal cancer	0.000365	0.0022	CcSEcCtD
Etoricoxib—Breast disorder—Methotrexate—esophageal cancer	0.000362	0.00218	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00036	0.00217	CcSEcCtD
Etoricoxib—Oedema—Cisplatin—esophageal cancer	0.000358	0.00216	CcSEcCtD
Etoricoxib—Anaphylactic shock—Cisplatin—esophageal cancer	0.000358	0.00216	CcSEcCtD
Etoricoxib—Visual impairment—Capecitabine—esophageal cancer	0.000358	0.00216	CcSEcCtD
Etoricoxib—Infection—Cisplatin—esophageal cancer	0.000356	0.00215	CcSEcCtD
Etoricoxib—Erythema multiforme—Capecitabine—esophageal cancer	0.000352	0.00212	CcSEcCtD
Etoricoxib—Nervous system disorder—Cisplatin—esophageal cancer	0.000351	0.00212	CcSEcCtD
Etoricoxib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000351	0.00211	CcSEcCtD
Etoricoxib—CYP1A2—lung—esophageal cancer	0.000349	0.0226	CbGeAlD
Etoricoxib—Skin disorder—Cisplatin—esophageal cancer	0.000348	0.0021	CcSEcCtD
Etoricoxib—Eye disorder—Capecitabine—esophageal cancer	0.000348	0.00209	CcSEcCtD
Etoricoxib—Tinnitus—Capecitabine—esophageal cancer	0.000347	0.00209	CcSEcCtD
Etoricoxib—PTGS2—digestive system—esophageal cancer	0.000346	0.0224	CbGeAlD
Etoricoxib—Flushing—Capecitabine—esophageal cancer	0.000345	0.00208	CcSEcCtD
Etoricoxib—Cardiac disorder—Capecitabine—esophageal cancer	0.000345	0.00208	CcSEcCtD
Etoricoxib—Anorexia—Cisplatin—esophageal cancer	0.000342	0.00206	CcSEcCtD
Etoricoxib—Pancreatitis—Methotrexate—esophageal cancer	0.000339	0.00204	CcSEcCtD
Etoricoxib—Angiopathy—Capecitabine—esophageal cancer	0.000337	0.00203	CcSEcCtD
Etoricoxib—Immune system disorder—Capecitabine—esophageal cancer	0.000336	0.00202	CcSEcCtD
Etoricoxib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000335	0.00202	CcSEcCtD
Etoricoxib—Arrhythmia—Capecitabine—esophageal cancer	0.000332	0.002	CcSEcCtD
Etoricoxib—Abdominal discomfort—Methotrexate—esophageal cancer	0.000332	0.002	CcSEcCtD
Etoricoxib—Alopecia—Capecitabine—esophageal cancer	0.000329	0.00198	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000327	0.00197	CcSEcCtD
Etoricoxib—Mental disorder—Capecitabine—esophageal cancer	0.000326	0.00196	CcSEcCtD
Etoricoxib—Erythema—Capecitabine—esophageal cancer	0.000324	0.00195	CcSEcCtD
Etoricoxib—Malnutrition—Capecitabine—esophageal cancer	0.000324	0.00195	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000321	0.00194	CcSEcCtD
Etoricoxib—Dyspnoea—Cisplatin—esophageal cancer	0.00032	0.00193	CcSEcCtD
Etoricoxib—Flatulence—Capecitabine—esophageal cancer	0.000319	0.00192	CcSEcCtD
Etoricoxib—Dysgeusia—Capecitabine—esophageal cancer	0.000317	0.00191	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000316	0.0019	CcSEcCtD
Etoricoxib—CYP2E1—lung—esophageal cancer	0.000314	0.0204	CbGeAlD
Etoricoxib—Decreased appetite—Cisplatin—esophageal cancer	0.000312	0.00188	CcSEcCtD
Etoricoxib—Muscle spasms—Capecitabine—esophageal cancer	0.000311	0.00188	CcSEcCtD
Etoricoxib—Pneumonia—Methotrexate—esophageal cancer	0.00031	0.00187	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000309	0.00186	CcSEcCtD
Etoricoxib—Infestation NOS—Methotrexate—esophageal cancer	0.000308	0.00186	CcSEcCtD
Etoricoxib—Infestation—Methotrexate—esophageal cancer	0.000308	0.00186	CcSEcCtD
Etoricoxib—Pain—Cisplatin—esophageal cancer	0.000306	0.00185	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000306	0.00184	CcSEcCtD
Etoricoxib—Vision blurred—Capecitabine—esophageal cancer	0.000305	0.00184	CcSEcCtD
Etoricoxib—Tremor—Capecitabine—esophageal cancer	0.000303	0.00183	CcSEcCtD
Etoricoxib—Renal failure—Methotrexate—esophageal cancer	0.000303	0.00183	CcSEcCtD
Etoricoxib—CYP3A4—digestive system—esophageal cancer	0.000302	0.0196	CbGeAlD
Etoricoxib—Stomatitis—Methotrexate—esophageal cancer	0.000301	0.00181	CcSEcCtD
Etoricoxib—Conjunctivitis—Methotrexate—esophageal cancer	0.0003	0.00181	CcSEcCtD
Etoricoxib—Anaemia—Capecitabine—esophageal cancer	0.000299	0.0018	CcSEcCtD
Etoricoxib—CYP2D6—digestive system—esophageal cancer	0.000298	0.0193	CbGeAlD
Etoricoxib—Feeling abnormal—Cisplatin—esophageal cancer	0.000295	0.00178	CcSEcCtD
Etoricoxib—Haematuria—Methotrexate—esophageal cancer	0.000294	0.00177	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000292	0.00176	CcSEcCtD
Etoricoxib—Epistaxis—Methotrexate—esophageal cancer	0.000291	0.00175	CcSEcCtD
Etoricoxib—PTGS2—lung—esophageal cancer	0.000289	0.0187	CbGeAlD
Etoricoxib—Palpitations—Capecitabine—esophageal cancer	0.000286	0.00172	CcSEcCtD
Etoricoxib—Cough—Capecitabine—esophageal cancer	0.000282	0.0017	CcSEcCtD
Etoricoxib—Hypertension—Capecitabine—esophageal cancer	0.000279	0.00168	CcSEcCtD
Etoricoxib—Haemoglobin—Methotrexate—esophageal cancer	0.000278	0.00168	CcSEcCtD
Etoricoxib—Haemorrhage—Methotrexate—esophageal cancer	0.000277	0.00167	CcSEcCtD
Etoricoxib—Hepatitis—Methotrexate—esophageal cancer	0.000277	0.00167	CcSEcCtD
Etoricoxib—Chest pain—Capecitabine—esophageal cancer	0.000276	0.00166	CcSEcCtD
Etoricoxib—Arthralgia—Capecitabine—esophageal cancer	0.000276	0.00166	CcSEcCtD
Etoricoxib—Pharyngitis—Methotrexate—esophageal cancer	0.000275	0.00166	CcSEcCtD
Etoricoxib—Anxiety—Capecitabine—esophageal cancer	0.000275	0.00165	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000274	0.00165	CcSEcCtD
Etoricoxib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000273	0.00165	CcSEcCtD
Etoricoxib—Urethral disorder—Methotrexate—esophageal cancer	0.000271	0.00163	CcSEcCtD
Etoricoxib—Dry mouth—Capecitabine—esophageal cancer	0.00027	0.00162	CcSEcCtD
Etoricoxib—Visual impairment—Methotrexate—esophageal cancer	0.000267	0.00161	CcSEcCtD
Etoricoxib—Confusional state—Capecitabine—esophageal cancer	0.000266	0.00161	CcSEcCtD
Etoricoxib—Oedema—Capecitabine—esophageal cancer	0.000264	0.00159	CcSEcCtD
Etoricoxib—Hypersensitivity—Cisplatin—esophageal cancer	0.000264	0.00159	CcSEcCtD
Etoricoxib—Infection—Capecitabine—esophageal cancer	0.000262	0.00158	CcSEcCtD
Etoricoxib—Erythema multiforme—Methotrexate—esophageal cancer	0.000262	0.00158	CcSEcCtD
Etoricoxib—Shock—Capecitabine—esophageal cancer	0.00026	0.00157	CcSEcCtD
Etoricoxib—Nervous system disorder—Capecitabine—esophageal cancer	0.000259	0.00156	CcSEcCtD
Etoricoxib—Eye disorder—Methotrexate—esophageal cancer	0.000259	0.00156	CcSEcCtD
Etoricoxib—Thrombocytopenia—Capecitabine—esophageal cancer	0.000259	0.00156	CcSEcCtD
Etoricoxib—Tinnitus—Methotrexate—esophageal cancer	0.000258	0.00156	CcSEcCtD
Etoricoxib—Asthenia—Cisplatin—esophageal cancer	0.000257	0.00155	CcSEcCtD
Etoricoxib—Cardiac disorder—Methotrexate—esophageal cancer	0.000257	0.00155	CcSEcCtD
Etoricoxib—Skin disorder—Capecitabine—esophageal cancer	0.000257	0.00155	CcSEcCtD
Etoricoxib—Anorexia—Capecitabine—esophageal cancer	0.000252	0.00152	CcSEcCtD
Etoricoxib—Angiopathy—Methotrexate—esophageal cancer	0.000251	0.00151	CcSEcCtD
Etoricoxib—Immune system disorder—Methotrexate—esophageal cancer	0.00025	0.00151	CcSEcCtD
Etoricoxib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000249	0.0015	CcSEcCtD
Etoricoxib—Diarrhoea—Cisplatin—esophageal cancer	0.000245	0.00148	CcSEcCtD
Etoricoxib—Alopecia—Methotrexate—esophageal cancer	0.000245	0.00147	CcSEcCtD
Etoricoxib—Mental disorder—Methotrexate—esophageal cancer	0.000243	0.00146	CcSEcCtD
Etoricoxib—Erythema—Methotrexate—esophageal cancer	0.000241	0.00145	CcSEcCtD
Etoricoxib—Malnutrition—Methotrexate—esophageal cancer	0.000241	0.00145	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000241	0.00145	CcSEcCtD
Etoricoxib—Insomnia—Capecitabine—esophageal cancer	0.000239	0.00144	CcSEcCtD
Etoricoxib—Dysgeusia—Methotrexate—esophageal cancer	0.000236	0.00142	CcSEcCtD
Etoricoxib—Dyspnoea—Capecitabine—esophageal cancer	0.000236	0.00142	CcSEcCtD
Etoricoxib—Dyspepsia—Capecitabine—esophageal cancer	0.000233	0.0014	CcSEcCtD
Etoricoxib—Decreased appetite—Capecitabine—esophageal cancer	0.00023	0.00138	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000228	0.00137	CcSEcCtD
Etoricoxib—Vomiting—Cisplatin—esophageal cancer	0.000228	0.00137	CcSEcCtD
Etoricoxib—Fatigue—Capecitabine—esophageal cancer	0.000228	0.00137	CcSEcCtD
Etoricoxib—Vision blurred—Methotrexate—esophageal cancer	0.000227	0.00137	CcSEcCtD
Etoricoxib—Rash—Cisplatin—esophageal cancer	0.000226	0.00136	CcSEcCtD
Etoricoxib—Pain—Capecitabine—esophageal cancer	0.000226	0.00136	CcSEcCtD
Etoricoxib—Constipation—Capecitabine—esophageal cancer	0.000226	0.00136	CcSEcCtD
Etoricoxib—Dermatitis—Cisplatin—esophageal cancer	0.000226	0.00136	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—esophageal cancer	0.000223	0.00134	CcSEcCtD
Etoricoxib—Feeling abnormal—Capecitabine—esophageal cancer	0.000218	0.00131	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000216	0.0013	CcSEcCtD
Etoricoxib—Nausea—Cisplatin—esophageal cancer	0.000213	0.00128	CcSEcCtD
Etoricoxib—Cough—Methotrexate—esophageal cancer	0.00021	0.00127	CcSEcCtD
Etoricoxib—Urticaria—Capecitabine—esophageal cancer	0.00021	0.00126	CcSEcCtD
Etoricoxib—Abdominal pain—Capecitabine—esophageal cancer	0.000209	0.00126	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—esophageal cancer	0.000205	0.00124	CcSEcCtD
Etoricoxib—Chest pain—Methotrexate—esophageal cancer	0.000205	0.00124	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000204	0.00123	CcSEcCtD
Etoricoxib—Confusional state—Methotrexate—esophageal cancer	0.000198	0.00119	CcSEcCtD
Etoricoxib—PTGS2—lymph node—esophageal cancer	0.000198	0.0128	CbGeAlD
Etoricoxib—Anaphylactic shock—Methotrexate—esophageal cancer	0.000197	0.00118	CcSEcCtD
Etoricoxib—Infection—Methotrexate—esophageal cancer	0.000195	0.00118	CcSEcCtD
Etoricoxib—Hypersensitivity—Capecitabine—esophageal cancer	0.000195	0.00117	CcSEcCtD
Etoricoxib—Nervous system disorder—Methotrexate—esophageal cancer	0.000193	0.00116	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—esophageal cancer	0.000193	0.00116	CcSEcCtD
Etoricoxib—Skin disorder—Methotrexate—esophageal cancer	0.000191	0.00115	CcSEcCtD
Etoricoxib—Asthenia—Capecitabine—esophageal cancer	0.00019	0.00114	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—esophageal cancer	0.000187	0.00113	CcSEcCtD
Etoricoxib—Pruritus—Capecitabine—esophageal cancer	0.000187	0.00113	CcSEcCtD
Etoricoxib—Diarrhoea—Capecitabine—esophageal cancer	0.000181	0.00109	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000179	0.00108	CcSEcCtD
Etoricoxib—Insomnia—Methotrexate—esophageal cancer	0.000178	0.00107	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—esophageal cancer	0.000175	0.00106	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—esophageal cancer	0.000175	0.00105	CcSEcCtD
Etoricoxib—Dizziness—Capecitabine—esophageal cancer	0.000175	0.00105	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—esophageal cancer	0.000173	0.00104	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—esophageal cancer	0.000171	0.00103	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00017	0.00102	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—esophageal cancer	0.00017	0.00102	CcSEcCtD
Etoricoxib—Pain—Methotrexate—esophageal cancer	0.000168	0.00101	CcSEcCtD
Etoricoxib—Vomiting—Capecitabine—esophageal cancer	0.000168	0.00101	CcSEcCtD
Etoricoxib—Rash—Capecitabine—esophageal cancer	0.000167	0.001	CcSEcCtD
Etoricoxib—Dermatitis—Capecitabine—esophageal cancer	0.000166	0.001	CcSEcCtD
Etoricoxib—Headache—Capecitabine—esophageal cancer	0.000166	0.000997	CcSEcCtD
Etoricoxib—Feeling abnormal—Methotrexate—esophageal cancer	0.000162	0.000976	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000161	0.000969	CcSEcCtD
Etoricoxib—Nausea—Capecitabine—esophageal cancer	0.000157	0.000946	CcSEcCtD
Etoricoxib—Urticaria—Methotrexate—esophageal cancer	0.000156	0.000941	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—esophageal cancer	0.000155	0.000937	CcSEcCtD
Etoricoxib—Hypersensitivity—Methotrexate—esophageal cancer	0.000145	0.000873	CcSEcCtD
Etoricoxib—Asthenia—Methotrexate—esophageal cancer	0.000141	0.00085	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—esophageal cancer	0.000139	0.000838	CcSEcCtD
Etoricoxib—Diarrhoea—Methotrexate—esophageal cancer	0.000135	0.000811	CcSEcCtD
Etoricoxib—Dizziness—Methotrexate—esophageal cancer	0.00013	0.000784	CcSEcCtD
Etoricoxib—Vomiting—Methotrexate—esophageal cancer	0.000125	0.000753	CcSEcCtD
Etoricoxib—Rash—Methotrexate—esophageal cancer	0.000124	0.000747	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—esophageal cancer	0.000124	0.000746	CcSEcCtD
Etoricoxib—Headache—Methotrexate—esophageal cancer	0.000123	0.000742	CcSEcCtD
Etoricoxib—Nausea—Methotrexate—esophageal cancer	0.000117	0.000704	CcSEcCtD
Etoricoxib—CYP1A2—Metabolism—SLC10A2—esophageal cancer	2.82e-05	0.00013	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ADH7—esophageal cancer	2.8e-05	0.00013	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PLCE1—esophageal cancer	2.8e-05	0.00013	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GNG7—esophageal cancer	2.79e-05	0.000129	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FBXW7—esophageal cancer	2.79e-05	0.000129	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GAPDH—esophageal cancer	2.79e-05	0.000129	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ENO1—esophageal cancer	2.78e-05	0.000129	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.77e-05	0.000128	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CRABP1—esophageal cancer	2.76e-05	0.000128	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PSME1—esophageal cancer	2.74e-05	0.000127	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PSME2—esophageal cancer	2.74e-05	0.000127	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CDKN1A—esophageal cancer	2.71e-05	0.000126	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ADH1B—esophageal cancer	2.69e-05	0.000125	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CALR—esophageal cancer	2.63e-05	0.000122	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GNG7—esophageal cancer	2.63e-05	0.000122	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ALDH2—esophageal cancer	2.61e-05	0.000121	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—TLR4—esophageal cancer	2.58e-05	0.00012	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EP300—esophageal cancer	2.58e-05	0.000119	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CA2—esophageal cancer	2.58e-05	0.000119	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TYMP—esophageal cancer	2.58e-05	0.000119	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.56e-05	0.000118	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.56e-05	0.000118	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FBXW7—esophageal cancer	2.54e-05	0.000118	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NOTCH2—esophageal cancer	2.54e-05	0.000118	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.52e-05	0.000116	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP26A1—esophageal cancer	2.51e-05	0.000116	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—EGFR—esophageal cancer	2.49e-05	0.000115	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GSTT1—esophageal cancer	2.49e-05	0.000115	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ADH1B—esophageal cancer	2.48e-05	0.000115	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ALDH2—esophageal cancer	2.46e-05	0.000114	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CYP2A6—esophageal cancer	2.46e-05	0.000114	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ADH1B—esophageal cancer	2.46e-05	0.000114	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.45e-05	0.000113	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALOX15—esophageal cancer	2.44e-05	0.000113	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—NOTCH1—esophageal cancer	2.42e-05	0.000112	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ADH7—esophageal cancer	2.39e-05	0.000111	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PLCE1—esophageal cancer	2.39e-05	0.000111	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TYMP—esophageal cancer	2.37e-05	0.00011	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.37e-05	0.00011	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TYMP—esophageal cancer	2.35e-05	0.000109	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTT1—esophageal cancer	2.34e-05	0.000108	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ENO1—esophageal cancer	2.33e-05	0.000108	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PTGS1—esophageal cancer	2.33e-05	0.000108	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTO1—esophageal cancer	2.33e-05	0.000108	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TPI1—esophageal cancer	2.33e-05	0.000108	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CYP2A6—esophageal cancer	2.31e-05	0.000107	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP26A1—esophageal cancer	2.3e-05	0.000107	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PSME2—esophageal cancer	2.3e-05	0.000106	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PSME1—esophageal cancer	2.3e-05	0.000106	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP26A1—esophageal cancer	2.28e-05	0.000106	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TGFBR2—esophageal cancer	2.26e-05	0.000104	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALOX15—esophageal cancer	2.25e-05	0.000104	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALDOB—esophageal cancer	2.23e-05	0.000103	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALOX15—esophageal cancer	2.23e-05	0.000103	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CASP8—esophageal cancer	2.22e-05	0.000103	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CREBBP—esophageal cancer	2.21e-05	0.000102	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EGFR—esophageal cancer	2.2e-05	0.000102	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—CREBBP—esophageal cancer	2.2e-05	0.000102	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS1—esophageal cancer	2.19e-05	0.000101	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ENO1—esophageal cancer	2.19e-05	0.000101	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.17e-05	0.000101	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CA1—esophageal cancer	2.17e-05	0.000101	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PSME2—esophageal cancer	2.16e-05	0.0001	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PSME1—esophageal cancer	2.16e-05	0.0001	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GAPDH—esophageal cancer	2.15e-05	9.95e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TPI1—esophageal cancer	2.14e-05	9.91e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTO1—esophageal cancer	2.14e-05	9.91e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SMAD4—esophageal cancer	2.14e-05	9.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CRABP1—esophageal cancer	2.13e-05	9.86e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTO1—esophageal cancer	2.12e-05	9.83e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TPI1—esophageal cancer	2.12e-05	9.83e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—PIK3CA—esophageal cancer	2.12e-05	9.81e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ADH1B—esophageal cancer	2.1e-05	9.72e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFBR2—esophageal cancer	2.06e-05	9.52e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.05e-05	9.5e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—esophageal cancer	2.05e-05	9.49e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALDOB—esophageal cancer	2.04e-05	9.42e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GNG7—esophageal cancer	2.03e-05	9.38e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TYMP—esophageal cancer	2.01e-05	9.29e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CA2—esophageal cancer	1.99e-05	9.2e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CYP1B1—esophageal cancer	1.98e-05	9.17e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.98e-05	9.15e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.96e-05	9.07e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.96e-05	9.07e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.95e-05	9.03e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SMAD4—esophageal cancer	1.95e-05	9.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.94e-05	8.99e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PIK3CA—esophageal cancer	1.91e-05	8.84e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—BCL2—esophageal cancer	1.9e-05	8.8e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.9e-05	8.8e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALDH2—esophageal cancer	1.9e-05	8.79e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CYP1B1—esophageal cancer	1.87e-05	8.63e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GNG7—esophageal cancer	1.86e-05	8.62e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CYP19A1—esophageal cancer	1.86e-05	8.62e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ERBB2—esophageal cancer	1.85e-05	8.55e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ADH7—esophageal cancer	1.85e-05	8.55e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.85e-05	8.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GNG7—esophageal cancer	1.85e-05	8.55e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TPI1—esophageal cancer	1.81e-05	8.4e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.81e-05	8.4e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTT1—esophageal cancer	1.81e-05	8.36e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP2A6—esophageal cancer	1.79e-05	8.26e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.78e-05	8.23e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CYP19A1—esophageal cancer	1.75e-05	8.11e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HIF1A—esophageal cancer	1.75e-05	8.08e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.75e-05	8.08e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.74e-05	8.05e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.73e-05	8.01e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—HMOX1—esophageal cancer	1.7e-05	7.87e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ENO1—esophageal cancer	1.69e-05	7.83e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS1—esophageal cancer	1.69e-05	7.83e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.67e-05	7.75e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KDR—esophageal cancer	1.67e-05	7.73e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.67e-05	7.72e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PSME1—esophageal cancer	1.67e-05	7.72e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PSME2—esophageal cancer	1.67e-05	7.72e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.66e-05	7.69e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.66e-05	7.68e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.65e-05	7.62e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.64e-05	7.6e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ABCB1—esophageal cancer	1.63e-05	7.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.63e-05	7.53e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.62e-05	7.5e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.62e-05	7.5e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—HMOX1—esophageal cancer	1.6e-05	7.4e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HIF1A—esophageal cancer	1.59e-05	7.38e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDKN1A—esophageal cancer	1.58e-05	7.31e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GNG7—esophageal cancer	1.58e-05	7.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NOTCH1—esophageal cancer	1.57e-05	7.28e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.56e-05	7.2e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ENO1—esophageal cancer	1.56e-05	7.2e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TYMP—esophageal cancer	1.55e-05	7.17e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ENO1—esophageal cancer	1.54e-05	7.14e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.54e-05	7.14e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ABCB1—esophageal cancer	1.54e-05	7.11e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PSME2—esophageal cancer	1.53e-05	7.1e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PSME1—esophageal cancer	1.53e-05	7.1e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PSME1—esophageal cancer	1.52e-05	7.04e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PSME2—esophageal cancer	1.52e-05	7.04e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.51e-05	6.97e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EP300—esophageal cancer	1.5e-05	6.96e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.48e-05	6.85e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.47e-05	6.79e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.46e-05	6.74e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS2—esophageal cancer	1.45e-05	6.71e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.44e-05	6.66e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOTCH1—esophageal cancer	1.44e-05	6.64e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CREBBP—esophageal cancer	1.43e-05	6.6e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.41e-05	6.51e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.4e-05	6.48e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TPI1—esophageal cancer	1.4e-05	6.48e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.39e-05	6.44e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.39e-05	6.41e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.35e-05	6.26e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.34e-05	6.21e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.33e-05	6.14e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.32e-05	6.12e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ENO1—esophageal cancer	1.32e-05	6.1e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.32e-05	6.1e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.31e-05	6.07e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—esophageal cancer	1.3e-05	6.03e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CREBBP—esophageal cancer	1.3e-05	6.02e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PSME1—esophageal cancer	1.3e-05	6.01e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PSME2—esophageal cancer	1.3e-05	6.01e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.29e-05	5.98e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—esophageal cancer	1.28e-05	5.93e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.28e-05	5.93e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NOS3—esophageal cancer	1.28e-05	5.91e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.24e-05	5.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.23e-05	5.71e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.23e-05	5.71e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.23e-05	5.71e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GNG7—esophageal cancer	1.22e-05	5.64e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.21e-05	5.6e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ERBB2—esophageal cancer	1.2e-05	5.53e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.18e-05	5.48e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS3—esophageal cancer	1.17e-05	5.39e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.14e-05	5.28e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.14e-05	5.25e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.13e-05	5.25e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.13e-05	5.21e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.12e-05	5.19e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CA—esophageal cancer	1.11e-05	5.15e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.1e-05	5.11e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CREBBP—esophageal cancer	1.09e-05	5.05e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERBB2—esophageal cancer	1.09e-05	5.05e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.09e-05	5.04e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.09e-05	5.02e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.08e-05	5e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.07e-05	4.97e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—esophageal cancer	1.06e-05	4.89e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.05e-05	4.88e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CREBBP—esophageal cancer	1.03e-05	4.75e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1A—esophageal cancer	1.02e-05	4.73e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.02e-05	4.71e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.02e-05	4.71e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PSME1—esophageal cancer	1e-05	4.64e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PSME2—esophageal cancer	1e-05	4.64e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—NOS3—esophageal cancer	9.76e-06	4.52e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EP300—esophageal cancer	9.72e-06	4.5e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HMOX1—esophageal cancer	9.62e-06	4.45e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.44e-06	4.37e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1A—esophageal cancer	9.32e-06	4.31e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ABCB1—esophageal cancer	9.23e-06	4.27e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NOS3—esophageal cancer	9.19e-06	4.25e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.96e-06	4.15e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EP300—esophageal cancer	8.87e-06	4.1e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	8.65e-06	4e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—esophageal cancer	8.47e-06	3.92e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS2—esophageal cancer	8.41e-06	3.89e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—esophageal cancer	8.28e-06	3.83e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.17e-06	3.78e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	8.14e-06	3.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CREBBP—esophageal cancer	7.92e-06	3.66e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—esophageal cancer	7.73e-06	3.58e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—esophageal cancer	7.56e-06	3.5e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—EP300—esophageal cancer	7.43e-06	3.44e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.42e-06	3.44e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CREBBP—esophageal cancer	7.28e-06	3.37e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CREBBP—esophageal cancer	7.22e-06	3.34e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CA—esophageal cancer	7.19e-06	3.33e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCB1—esophageal cancer	7.13e-06	3.3e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NOS3—esophageal cancer	7.09e-06	3.28e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—EP300—esophageal cancer	6.99e-06	3.23e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.98e-06	3.23e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—esophageal cancer	6.96e-06	3.22e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CA—esophageal cancer	6.56e-06	3.04e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NOS3—esophageal cancer	6.52e-06	3.02e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS2—esophageal cancer	6.49e-06	3e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NOS3—esophageal cancer	6.47e-06	2.99e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CREBBP—esophageal cancer	6.17e-06	2.86e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS2—esophageal cancer	5.96e-06	2.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS2—esophageal cancer	5.91e-06	2.74e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NOS3—esophageal cancer	5.52e-06	2.56e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CA—esophageal cancer	5.49e-06	2.54e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—EP300—esophageal cancer	5.39e-06	2.5e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CA—esophageal cancer	5.17e-06	2.39e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS2—esophageal cancer	5.05e-06	2.34e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—EP300—esophageal cancer	4.96e-06	2.3e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—EP300—esophageal cancer	4.92e-06	2.28e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.76e-06	2.2e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NOS3—esophageal cancer	4.26e-06	1.97e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—EP300—esophageal cancer	4.2e-06	1.94e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CA—esophageal cancer	3.99e-06	1.85e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.9e-06	1.8e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	3.67e-06	1.7e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CA—esophageal cancer	3.64e-06	1.68e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—EP300—esophageal cancer	3.24e-06	1.5e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.11e-06	1.44e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.4e-06	1.11e-05	CbGpPWpGaD
